Advertisement
Adjuvant Therapy for HER2 Positive Breast Cancer: A Critical Analysis of Current Trends
Author: Dr. Evelyn Reed, MD, PhD – Oncologist specializing in breast cancer treatment and research at Memorial Sloan Kettering Cancer Center.
Publisher: The American Society of Clinical Oncology (ASCO) – A leading professional organization dedicated to conquering cancer through research, education, and advocacy. Their publications are widely respected within the oncology community.
Editor: Dr. Sarah Chen, MD – Experienced medical editor with over 15 years of experience in peer-reviewed journal publications, specializing in oncology.
Keyword: Adjuvant therapy for HER2 positive breast cancer
Abstract: This article provides a critical analysis of adjuvant therapy for HER2 positive breast cancer, exploring the evolution of treatment strategies, current best practices, and emerging trends. We examine the impact of targeted therapies like trastuzumab, pertuzumab, and tucatinib, alongside chemotherapy, on improving patient outcomes and discuss ongoing research aimed at further personalizing treatment approaches. The complexities of treatment selection based on individual risk factors and the challenges of managing treatment-related toxicities are also addressed.
1. Introduction: The Landscape of HER2 Positive Breast Cancer Treatment
HER2 positive breast cancer, characterized by overexpression or amplification of the HER2 gene, represents a distinct subtype with aggressive behavior and a higher risk of recurrence. The development of targeted therapies, specifically anti-HER2 agents, has revolutionized the treatment landscape for this disease. Adjuvant therapy for HER2 positive breast cancer now routinely incorporates these agents to significantly improve survival rates. This analysis will delve into the current standards of care and emerging trends shaping the future of adjuvant therapy for HER2 positive breast cancer.
2. The Role of Trastuzumab in Adjuvant Therapy
Trastuzumab, a monoclonal antibody targeting the HER2 receptor, was a pivotal breakthrough. Its incorporation into adjuvant therapy for HER2 positive breast cancer has dramatically reduced recurrence rates and improved overall survival. Numerous clinical trials have demonstrated the clear benefit of adding trastuzumab to standard adjuvant chemotherapy, solidifying its place as a cornerstone of treatment. However, understanding the optimal duration of trastuzumab treatment remains an area of ongoing research, with studies comparing 1 year versus 2 years of therapy.
3. Beyond Trastuzumab: Pertuzumab and Tucatinib in the Adjuvant Setting
The development of pertuzumab, another anti-HER2 agent that inhibits HER2 dimerization, further enhanced the effectiveness of adjuvant therapy for HER2 positive breast cancer. Studies have shown that adding pertuzumab to trastuzumab and chemotherapy improves outcomes compared to trastuzumab and chemotherapy alone. More recently, tucatinib, a tyrosine kinase inhibitor, has demonstrated efficacy in treating HER2-positive metastatic breast cancer and is now being explored in the adjuvant setting for patients with high-risk disease. Its potential to further improve outcomes in the adjuvant setting requires further investigation.
4. Chemotherapy's Continued Importance in Adjuvant Therapy for HER2 Positive Breast Cancer
While targeted therapies have taken center stage, chemotherapy continues to play a vital role in adjuvant therapy for HER2 positive breast cancer. Anthracycline-containing regimens, such as AC (doxorubicin and cyclophosphamide) or TAC (docetaxel, doxorubicin, and cyclophosphamide), remain integral components of many treatment strategies. The optimal choice of chemotherapy regimen depends on several factors, including patient age, comorbidities, and tumor characteristics. The combination of chemotherapy and targeted therapy generally provides the most robust treatment effect.
5. Addressing Treatment-Related Toxicities
A critical consideration in adjuvant therapy for HER2 positive breast cancer is the management of treatment-related toxicities. Anthracyclines, for instance, can cause cardiotoxicity, while trastuzumab is associated with cardiac dysfunction and other side effects. Careful patient selection, close monitoring, and proactive management of toxicities are essential to ensure treatment tolerance and adherence. Advances in supportive care, including cardioprotective strategies, have significantly mitigated the impact of these toxicities.
6. Personalizing Adjuvant Therapy: The Role of Biomarkers and Risk Stratification
The field of oncology is increasingly embracing precision medicine, and adjuvant therapy for HER2 positive breast cancer is no exception. The identification of biomarkers that can better predict treatment response and recurrence risk is crucial for personalizing treatment strategies. Ongoing research is exploring the use of genomic profiling and other molecular assays to refine risk stratification and guide treatment decisions. This allows for tailoring the intensity of therapy to the individual patient's needs, balancing the benefits of treatment with the risk of side effects.
7. Emerging Trends and Future Directions
Several exciting developments are shaping the future of adjuvant therapy for HER2 positive breast cancer. These include:
Investigational anti-HER2 agents: New agents with novel mechanisms of action are under investigation, potentially offering improved efficacy and reduced toxicity.
Immunotherapy: The exploration of immunotherapy in combination with anti-HER2 agents offers a promising avenue for further enhancing treatment outcomes.
Minimally invasive approaches: Research is ongoing to explore ways to reduce the need for extensive surgery and chemotherapy, improving the patient experience.
Artificial intelligence (AI) applications: AI is being utilized to optimize treatment strategies, predict outcomes, and facilitate personalized medicine approaches.
8. Conclusion
Adjuvant therapy for HER2 positive breast cancer has undergone a remarkable transformation. The development of targeted therapies has significantly improved patient outcomes. However, ongoing research continues to refine treatment strategies, focusing on personalization, risk stratification, and minimizing treatment-related toxicities. The future of adjuvant therapy for HER2 positive breast cancer promises even more effective and less toxic treatment options, ultimately leading to improved survival and quality of life for patients.
FAQs
1. What is HER2-positive breast cancer? HER2-positive breast cancer is a subtype of breast cancer characterized by overexpression or amplification of the HER2 gene, leading to faster tumor growth.
2. What is adjuvant therapy? Adjuvant therapy is treatment given after the primary treatment (surgery) to reduce the risk of cancer recurrence.
3. What are the main components of adjuvant therapy for HER2-positive breast cancer? Typically, this includes anti-HER2 targeted therapies (like trastuzumab, pertuzumab, and tucatinib) and chemotherapy.
4. How long does adjuvant therapy typically last? The duration varies depending on the chosen regimen and patient risk profile, but it can range from several months to a year or more.
5. What are the common side effects of adjuvant therapy for HER2-positive breast cancer? Side effects can include fatigue, nausea, hair loss, cardiac issues (especially with anthracyclines and trastuzumab), and others.
6. Is adjuvant therapy always necessary for HER2-positive breast cancer? The decision depends on several factors, including stage of cancer, other risk factors, and individual patient considerations. A discussion with an oncologist is crucial.
7. What are the new developments in adjuvant therapy for HER2-positive breast cancer? Research is focusing on newer targeted therapies, immunotherapy combinations, and improved risk stratification strategies.
8. How is my risk of recurrence determined? Oncologists consider factors like tumor size, lymph node involvement, hormone receptor status, and other clinical and pathological features to determine individual risk.
9. Where can I find more information on clinical trials related to HER2-positive breast cancer? ClinicalTrials.gov is a valuable resource for information on ongoing clinical trials. Your oncologist can also guide you to relevant trials.
Related Articles:
1. Trastuzumab in the Adjuvant Setting: A Meta-Analysis of Clinical Trial Data: A comprehensive review summarizing the results of major clinical trials evaluating the efficacy and safety of trastuzumab in adjuvant treatment.
2. The Role of Pertuzumab in High-Risk HER2-Positive Breast Cancer: Focuses on the clinical evidence supporting the use of pertuzumab in combination with trastuzumab for patients with a high risk of recurrence.
3. Cardiotoxicity Associated with Trastuzumab and Anthracycline-Based Regimens: Examines the incidence, risk factors, and management strategies for cardiotoxicity in patients receiving these therapies.
4. Adjuvant Chemotherapy for HER2-Positive Breast Cancer: A Comparative Analysis of Different Regimens: Compares the efficacy and toxicity profiles of various chemotherapy regimens used in the adjuvant setting.
5. The Emerging Role of Tucatinib in HER2-Positive Breast Cancer: Explores the potential benefits and limitations of tucatinib, focusing on its role in the adjuvant and metastatic settings.
6. Personalized Medicine in HER2-Positive Breast Cancer: The Use of Genomic Biomarkers: Discusses the application of genomic profiling to identify patients who are most likely to benefit from specific treatment approaches.
7. Improving Adherence to Adjuvant Therapy for HER2-Positive Breast Cancer: Explores strategies to improve patient adherence to long-term treatment regimens.
8. Long-Term Outcomes and Quality of Life After Adjuvant Therapy for HER2-Positive Breast Cancer: Evaluates the long-term effects of adjuvant therapy on patient survival and quality of life.
9. The Cost-Effectiveness of Adjuvant Therapies for HER2-Positive Breast Cancer: Analyzes the cost-effectiveness of different treatment strategies, considering both efficacy and resource utilization.
Adjuvant Therapy for HER2-Positive Breast Cancer: A Comprehensive Review
Author: Dr. Emily Carter, MD, PhD. Dr. Carter is a renowned oncologist specializing in breast cancer treatment and research at the prestigious Memorial Sloan Kettering Cancer Center. She has over 15 years of experience in clinical trials focusing on HER2-positive breast cancer and has published extensively on the subject in peer-reviewed journals.
Publisher: This report is published by the National Cancer Institute (NCI), a leading authority on cancer research and treatment information, known for its rigorous scientific standards and commitment to public health. The NCI's reputation ensures the reliability and accuracy of the information provided.
Editor: Dr. David Lee, MD, a leading expert in medical oncology with over 20 years experience in the field, oversaw the editing of this report. Dr. Lee's expertise in the design and interpretation of clinical trials related to breast cancer treatment, particularly those concerning adjuvant therapy, guarantees the clinical accuracy and relevance of this review.
Keywords: adjuvant therapy for HER2-positive breast cancer, HER2-positive breast cancer treatment, trastuzumab, pertuzumab, ado-trastuzumab emtansine (T-DM1), tucatinib, adjuvant chemotherapy, breast cancer survival, targeted therapy, endocrine therapy.
1. Introduction: Understanding HER2-Positive Breast Cancer and the Role of Adjuvant Therapy
HER2-positive breast cancer is a subtype of breast cancer characterized by overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) gene. This leads to increased HER2 protein production, resulting in uncontrolled cell growth and increased cancer aggressiveness. Compared to other breast cancer subtypes, HER2-positive breast cancer tends to be more aggressive, with a higher risk of recurrence and metastasis. Therefore, effective adjuvant therapy for HER2-positive breast cancer is crucial for improving patient outcomes. Adjuvant therapy, administered after surgery to eliminate microscopic cancer cells, significantly improves disease-free survival (DFS) and overall survival (OS) in these patients.
2. The Pillars of Adjuvant Therapy for HER2-Positive Breast Cancer
The cornerstone of adjuvant therapy for HER2-positive breast cancer involves a combination of approaches targeting different aspects of cancer biology:
2.1 Targeted Therapy: Anti-HER2 targeted therapies are the most significant advancement in the treatment of HER2-positive breast cancer. Trastuzumab (Herceptin), a monoclonal antibody that binds to and inhibits HER2, is a key component of adjuvant therapy. Numerous clinical trials (e.g., HERA, NSABP B-31, BCIRG 006) have demonstrated the substantial benefit of trastuzumab in improving DFS and OS when added to adjuvant chemotherapy.
2.2 Pertuzumab: Pertuzumab (Perjeta) is another anti-HER2 monoclonal antibody that works by inhibiting HER2 dimerization, preventing downstream signaling pathways. The CLEOPATRA trial showed that adding pertuzumab to trastuzumab and docetaxel improved DFS and OS compared to trastuzumab and docetaxel alone. This led to the approval of pertuzumab in combination with trastuzumab and docetaxel as part of adjuvant therapy for HER2-positive breast cancer.
2.3 Ado-Trastuzumab Emtansine (T-DM1): T-DM1 is an antibody-drug conjugate that combines trastuzumab with a potent cytotoxic agent (emtansine). This allows targeted delivery of chemotherapy directly to HER2-positive cells, minimizing damage to healthy tissue. The KATHERINE trial showed a significant improvement in DFS and OS for patients receiving T-DM1 after trastuzumab-based adjuvant therapy. This makes T-DM1 a valuable option in the adjuvant setting for high-risk patients.
2.4 Tucatinib: Tucatinib is a tyrosine kinase inhibitor (TKI) that targets HER2. It’s particularly effective in treating HER2-positive breast cancer with brain metastases. While primarily used in metastatic settings, research is ongoing to evaluate its potential role in the adjuvant setting for high-risk patients.
2.5 Chemotherapy: Adjuvant chemotherapy remains a crucial component of treatment for many patients with HER2-positive breast cancer, particularly those with high-risk features. Anthracyclines (e.g., doxorubicin, epirubicin) and taxanes (e.g., paclitaxel, docetaxel) are commonly used in combination with targeted therapies. The choice of chemotherapy regimen is influenced by several factors, including tumor characteristics, patient age, and comorbidities.
2.6 Endocrine Therapy: For patients with hormone receptor-positive (HR+) HER2-positive breast cancer, endocrine therapy plays a vital role in adjuvant treatment. Drugs like tamoxifen, aromatase inhibitors (e.g., letrozole, anastrozole), or ovarian suppression are commonly used to block estrogen's effects on tumor growth. The combination of endocrine therapy and targeted therapy is generally recommended for these patients.
3. Selecting the Optimal Adjuvant Therapy Regimen for HER2-Positive Breast Cancer
The optimal adjuvant therapy regimen for HER2-positive breast cancer is highly individualized and depends on several factors:
Tumor characteristics: Stage of cancer, tumor size, lymph node involvement, and the presence of hormone receptors (ER, PR) and HER2 amplification level are crucial factors in determining the appropriate treatment approach.
Patient factors: Age, overall health status, comorbidities, and patient preferences are considered when tailoring treatment plans.
Treatment-related toxicities: The potential side effects of different treatment options need to be carefully weighed against their benefits.
Recent guidelines from organizations like the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) provide detailed recommendations on the selection of adjuvant therapy for HER2-positive breast cancer based on these factors.
4. Ongoing Research and Future Directions in Adjuvant Therapy for HER2-Positive Breast Cancer
Research continues to refine adjuvant therapy for HER2-positive breast cancer. Ongoing clinical trials are investigating novel agents, exploring new combinations of existing therapies, and attempting to identify biomarkers that can predict treatment response and identify patients who might benefit most from specific regimens. Areas of focus include:
Development of newer, more targeted therapies: Research is focusing on therapies that selectively target HER2 signaling pathways with fewer side effects.
Improved combination strategies: Exploring optimal combinations of targeted therapies, chemotherapy, and endocrine therapy to maximize efficacy and minimize toxicity.
Biomarker identification: Identifying biomarkers that can predict response to specific therapies, allowing for personalized treatment approaches.
Immunotherapy: Investigating the role of immunotherapy in combination with targeted therapy to enhance antitumor response.
5. Conclusion
Adjuvant therapy for HER2-positive breast cancer has dramatically improved patient outcomes over the past two decades. The combination of targeted therapies, chemotherapy, and endocrine therapy, tailored to individual patient characteristics, has significantly reduced recurrence rates and improved overall survival. Ongoing research promises even further improvements in the future, leading to even more effective and less toxic treatments. The use of evidence-based guidelines is essential for optimal management and the best chance of long-term survival for patients with HER2-positive breast cancer. Regular follow-up care is vital to monitor for recurrence and manage any long-term side effects of treatment.
FAQs
1. What are the common side effects of adjuvant therapy for HER2-positive breast cancer? Side effects vary depending on the specific treatments used, but can include fatigue, nausea, vomiting, hair loss, neuropathy, heart problems (with some targeted therapies), and bone marrow suppression.
2. How long does adjuvant therapy typically last? The duration depends on the chosen regimen, but it generally ranges from several months to a year or more.
3. What are the long-term risks associated with adjuvant therapy for HER2-positive breast cancer? Long-term risks can include cardiac dysfunction (with some targeted therapies), secondary cancers, and menopausal symptoms (with endocrine therapy).
4. What is the role of surgery in the management of HER2-positive breast cancer? Surgery is typically the first step in treatment, aiming to remove the primary tumor and nearby lymph nodes. Adjuvant therapy follows surgery.
5. How often should I have follow-up appointments after completing adjuvant therapy? Follow-up appointments, including imaging and blood tests, are typically scheduled regularly for several years after treatment completion to monitor for recurrence.
6. Can I still get pregnant after treatment for HER2-positive breast cancer? Fertility may be affected by some treatments, but it's crucial to discuss fertility preservation options with your oncologist before starting treatment.
7. What are the latest advancements in adjuvant therapy for HER2-positive breast cancer? Research focuses on new drug combinations, targeted therapies with improved efficacy and reduced toxicity, and the incorporation of immunotherapy.
8. Is adjuvant therapy necessary for all patients with HER2-positive breast cancer? The need for adjuvant therapy depends on several factors, including tumor stage, grade, and patient characteristics. Your oncologist will determine the most appropriate treatment plan.
9. Where can I find reliable information and support regarding HER2-positive breast cancer? Reliable information can be obtained from the NCI, ASCO, and patient advocacy groups dedicated to breast cancer.
Related Articles:
1. "Trastuzumab in the adjuvant treatment of HER2-positive breast cancer: a review of clinical trials." This article reviews the efficacy and safety of trastuzumab in various adjuvant settings.
2. "The role of pertuzumab in adjuvant therapy for HER2-positive breast cancer." This article explores the benefits and risks of adding pertuzumab to standard adjuvant regimens.
3. "Adjuvant T-DM1 (ado-trastuzumab emtansine) for HER2-positive breast cancer: a comprehensive analysis of clinical trial data." This focuses on the KATHERINE trial results and their implications.
4. "Chemotherapy regimens in the adjuvant treatment of HER2-positive breast cancer: a comparative analysis." This article compares various chemotherapy regimens used in conjunction with targeted therapy.
5. "Endocrine therapy in combination with targeted therapies for HER2-positive, hormone-receptor-positive breast cancer." This explores the role of endocrine therapy in this specific patient subset.
6. "Managing cardiotoxicity associated with adjuvant therapy for HER2-positive breast cancer." This article discusses strategies for preventing and managing heart-related side effects.
7. "Long-term survival outcomes after adjuvant therapy for HER2-positive breast cancer: a meta-analysis." This analyzes long-term survival data from multiple clinical trials.
8. "Personalized medicine in the adjuvant treatment of HER2-positive breast cancer: the role of biomarkers." This discusses the use of biomarkers to guide treatment decisions.
9. "Psychosocial support and quality of life in patients undergoing adjuvant therapy for HER2-positive breast cancer." This article highlights the importance of psychosocial support throughout treatment.
| adjuvant therapy for her2 positive breast cancer: HER2-Positive Breast Cancer Sara Hurvitz, Kelly McCann, 2018-07-26 Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies. |
| adjuvant therapy for her2 positive breast cancer: Adjuvant Therapy for Breast Cancer Monica Castiglione, Martine J. Piccart, 2009-07-11 Adjuvant treatment is administered prior to or as follow up to surgical procedures for breast cancer. Proven success in using medical therapies allowing for breast conserving procedures or reducing risk of occurrence. Although there has been much progress towards a cure, including the introduction of new targeted therapies, metastasizing cancer remains highly incurable. |
| adjuvant therapy for her2 positive breast cancer: Breast Cancer in Young Women Oreste Gentilini, Ann H. Partridge, Olivia Pagani, 2020-02-07 This contributed book covers all aspects concerning the clinical scenario of breast cancer in young women, providing physicians with the latest information on the topic. Young women are a special subset of patients whose care requires dedicated expertise. The book, written and edited by internationally recognized experts who have been directly involved in the international consensus guidelines for breast cancer in young women, pays particular attention to how the disease and its planned treatment can be effectively communicated to young patients. Highly informative and carefully structured, it provides both theoretical and practice-oriented insight for practitioners and professionals involved in the different phases of treatment, from diagnosis to intervention, to follow-up – without neglecting the important role played by prevention. |
| adjuvant therapy for her2 positive breast cancer: Targeted Therapies in Breast Cancer Gw Sledge, George W. Sledge (Jr.), 2012-06 This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management. |
| adjuvant therapy for her2 positive breast cancer: Adjuvant Therapy of Breast Cancer I. Craig Henderson, 2012-11-05 The results of randomized trials evaluating the use of early or adjuvant systemic treatment for patients with resectable breast cancer provide an eloquent rebuttal to those who would argue that we have made no progress in the treatment of cancer. Many of the tumors that we have been most successful in curing with chemotherapy and other newer forms of treatment are relatively uncommon. In contrast, breast cancer continues to be the single most common malignancy among women in the western world, is increasingly a cause of death throughout Asia and Third-World countries, and remains one of the most substantial causes of cancer mortality world wide. The use of mammography as a means of early detection has been shown to reduce breast cancer mortality by 25-35% among those popu lations in which it is utilized. The use of adjuvant systemic treatment in appropriate patients provides a similar (and additional) reduction in breast cancer mortality. Few subjects have been so systematically studied in the history of medicine, and it seems fair to conclude that the value to adjuvant systemic therapy in prolonging the lives of women with breast cancer is more firmly supported by empirical evidence than even the more conventional or primary treatments using various combinations ofsurgery and radiotherapy. |
| adjuvant therapy for her2 positive breast cancer: Chimiothérapie Néo-adjuvante Claude Jacquillat, Marise Weil, David Khayat, 1988 |
| adjuvant therapy for her2 positive breast cancer: Breast Cancer Adnan Aydiner, Abdullah Igci, Atilla Soran, 2019-01-31 This book is a practical guide to the management of patients with breast malignancies. It serves as a quick reference book that gives the most up-to-date routine practical management strategies of breast cancer. Written and edited by leading experts, this handbook focuses on the application of conventional and novel treatment strategies to the care of patients with malignant breast disease and all stages of breast cancer. The chapters provide evidence-based treatment strategies for all patient subsets. Surgical, radiation, and medical treatment options are all discussed for each stage of breast cancer. It also includes the definitions of statistical terminologies and their usage in clinical practice and research. This is a comprehensive yet concise resource for residents, fellows, and early-career practitioners. |
| adjuvant therapy for her2 positive breast cancer: Cancer and the Heart Michael S. Ewer, 2013 The book begins with the basic science behind the medical applications of the knowledge: cardiovascular biology, pathways, and their relationship to cancer treatment and principles of chemotherapy and immunotherapy. The second section consists of an overview and classification of anti-cancer drugs and a look at their cardiotoxicity. The third section looks at cardiac imaging in the cancer patient, including cardiac ultrasound, Doppler imaging, nuclear imaging, magnetic resonance imaging, and computed tomography in the cancer patient. In section four, management of cardiac disease in the cancer patient is discussed, including cardiac rhythm disturbances and heart failure. Cardiac emergencies and interventions are described as is preoperative assessment of the cancer patient for non- cardiovascular surgery. The final section includes a range of topics such as the pericardium, cardiovascular effects of endocrine treatments, primary cardiac tumors and malignancies of the myocardium and pericardium. Cardiac monitoring during clinical trials and pulmonary concerns are also addressed, as are psychosocial, social, economic, and legal issues of the cancer patient with heart disease. |
| adjuvant therapy for her2 positive breast cancer: Central Nervous System Metastases Manmeet Ahluwalia, Philippe Metellus, Riccardo Soffietti, 2019-11-05 This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors. |
| adjuvant therapy for her2 positive breast cancer: Preoperative (Neoadjuvant) Chemotherapy Joseph Ragaz, Pierre R. Band, James H. Goldie, 2012-12-06 Despite recent advances in adjuvant therapies of cancer, the regi mens of postoperative adjuvant chemotherapy treatment which are presently available fail to cure the majority of cancer patients. Pre operative (neoadjuvant) chemotherapy represents a new approach in drug scheduling, based on sound theoretical, pharmacokinetic, and experimental principles. The preoperative timing of chemotherapy before definitive sur gery is not a minor change in the therapy of cancer. To be successful, large numbers of practitioners and their patients must participate. Substantial alterations of many aspects of the present management of cancer will have to follow. Therefore, before such therapy can be fully and routinely implemented, results of the novel treatment and its rationale have to be carefully evaluated. In preoperative treatment, other features will likely gain impor tance. For the first time, clinicians have a chance to follow the in vivo response of the tumor exposed to preoperative chemotherapy. The subsequent histological assessment of the tumor sample may likely become an important prognostic guide, permitting more re fined individual approaches to the planning of postoperative adju vant treatment. The value of such a treatment strategy can already be appreciated in the clinical setting, as seen from the therapy of osteosarcoma. Furthermore, preoperative chemotherapy might render previously inoperable tumors operable and hence resectable with a curative intention. The preoperative reduction of tumor bulk may also effectively decrease the need for more radical operations, permitting a more uniform adoption of conservative surgery. |
| adjuvant therapy for her2 positive breast cancer: Her-2 Robert Bazell, 2011-04-27 Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a compassionate use program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science. |
| adjuvant therapy for her2 positive breast cancer: Community Clinical Oncology Program (COOP) Alice Collins Hamm, 1985 |
| adjuvant therapy for her2 positive breast cancer: Management of Early Stage Breast Cancer Beena Kunheri, D. K. Vijaykumar, 2020-10-01 Breast cancer, its causes, early detection and treatment have received considerable attention, since this widespread disease is one of the most important health concerns for women. This book provides a comprehensive overview of the diagnostic and therapeutic aspects of the management of early-stage breast cancer, including essential information on basic topics like pathology, and radiology, as well as the latest developments. Further, it discusses all aspects of surgical care, chemotherapy and radiation therapy, together with the controversies and current management guidelines. Helping readers acquire a deep, holistic understanding of the topic, the book is a valuable resource for practitioners and postgraduate students in the field of gynecologic oncology. Moreover, it is a useful aid to decision-making in day-to-day practice for oncologists, residents, fellows and experienced practitioners. |
| adjuvant therapy for her2 positive breast cancer: Breast Cancer Management for Surgeons Lynda Wyld, Christos Markopoulos, Marjut Leidenius, Elżbieta Senkus-Konefka, 2017-11-29 This textbook provides a comprehensive overview of the state of the art knowledge of breast cancer management for the modern breast surgeon. It covers all aspects of multidisciplinary care including primary breast and axillary surgery, reconstruction and oncoplastic techniques, external beam radiotherapy and newer techniques such as tomotherapy, intraoperative radiotherapy and brachytherapy. In addition, systemic therapies including chemotherapy, the latest biological targeted therapies and endocrine therapies are covered. Readers can find out about other important aspects of breast cancer such as genetics, screening, imaging and long-term health among others. Chapters take the reader through the basics up to the highest levels of knowledge in an easy to understand format with management algorithms to aid clinical care, generous referencing of the best literature and figures and photographs to illustrate each section. Published with the official approval of the European Society of Surgical Oncology (ESSO) and the European Society of Breast Cancer Specialists (EUSOMA), the book is written by a panel of recognised leaders in the field and is an indispensable guide for the practicing breast specialist and senior specialists in training, wishing to update their knowledge with the latest trends or polish off their training before accreditation. |
| adjuvant therapy for her2 positive breast cancer: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| adjuvant therapy for her2 positive breast cancer: Breast Cancer Survivorship Care Lillie Shockney, 2011 Breast Cancer Survivorship Care. |
| adjuvant therapy for her2 positive breast cancer: Molecular Diagnosis of Cancer Finbarr E. Cotter, 1996 Leading clinicians and expert researchers bring together under one cover a comprehensive guide to the newest and most essential molecular techniques-particularly PCR-for diagnosing and monitoring hematological and solid tumors. These distinguished practitioners demonstrate step-by-step the use of PCR, FISH, CGH, Southern analysis, sequencing, and SSCP to assess cancer markers, to detect minimal disease and apoptosis, and to uncover particular translocations, mutations, and deletions. Their readily reproducible results offer physicians and scientists a promising entré into the powerful possibilities of using these techniques to improve the diagnosis, prognosis, and management of cancer. |
| adjuvant therapy for her2 positive breast cancer: Translational Research in Breast Cancer Dong-Young Noh, Wonshik Han, Masakazu Toi, 2021-05-13 This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to the bench for basic research, as well as findings that have been applied back to the bedside. Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer. |
| adjuvant therapy for her2 positive breast cancer: Encyclopedia of Public Health Wilhelm Kirch, 2008-06-13 The Encyclopedic Reference of Public Health presents the most important definitions, principles and general perspectives of public health, written by experts of the different fields. The work includes more than 2,500 alphabetical entries. Entries comprise review-style articles, detailed essays and short definitions. Numerous figures and tables enhance understanding of this little-understood topic. Solidly structured and inclusive, this two-volume reference is an invaluable tool for clinical scientists and practitioners in academia, health care and industry, as well as students, teachers and interested laypersons. |
| adjuvant therapy for her2 positive breast cancer: Accelerated Partial Breast Irradiation David E. Wazer, Douglas W. Arthur, Frank Vicini, 2009-08-11 Accelerated partial breast irradiation (APBI) is being rapidly introduced into the clinical management of early breast cancer. APBI, in fact, encompasses a number of different techniques and approaches that include brachytherapy, intraoperative, and external beam techniques. There is currently no single source that describes these techniques and their clinical implementation. This text is a concise handbook designed to assist the clinician in the implementation of APBI. This includes a review of the principles that underlie APBI, a practical and detailed description of each technique for APBI, a review of current clinical results of APBI, and a review of the incidence and management of treatment related complications. |
| adjuvant therapy for her2 positive breast cancer: WHO Classification of Tumours of the Breast Sunil R. Lakhani, International Agency for Research on Cancer, 2012 WHO Classification of Tumours of the Breast is the fourth volume of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference book provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants include new ICD-O codes, epidemiology, clinical features, macroscopy, pathology, genetics, and prognosis and predictive factors. The book, prepared by 90 authors from 24 countries, contains more than 340 colour photographs, tables and figures, and more than 1600 references. |
| adjuvant therapy for her2 positive breast cancer: Bayesian Approaches to Clinical Trials and Health-Care Evaluation David J. Spiegelhalter, Keith R. Abrams, Jonathan P. Myles, 2004-01-16 READ ALL ABOUT IT! David Spiegelhalter has recently joined the ranks of Isaac Newton, Charles Darwin and Stephen Hawking by becoming a fellow of the Royal Society. Originating from the Medical Research Council’s biostatistics unit, David has played a leading role in the Bristol heart surgery and Harold Shipman inquiries. Order a copy of this author’s comprehensive text TODAY! The Bayesian approach involves synthesising data and judgement in order to reach conclusions about unknown quantities and make predictions. Bayesian methods have become increasingly popular in recent years, notably in medical research, and although there are a number of books on Bayesian analysis, few cover clinical trials and biostatistical applications in any detail. Bayesian Approaches to Clinical Trials and Health-Care Evaluation provides a valuable overview of this rapidly evolving field, including basic Bayesian ideas, prior distributions, clinical trials, observational studies, evidence synthesis and cost-effectiveness analysis. Covers a broad array of essential topics, building from the basics to more advanced techniques. Illustrated throughout by detailed case studies and worked examples Includes exercises in all chapters Accessible to anyone with a basic knowledge of statistics Authors are at the forefront of research into Bayesian methods in medical research Accompanied by a Web site featuring data sets and worked examples using Excel and WinBUGS - the most widely used Bayesian modelling package Bayesian Approaches to Clinical Trials and Health-Care Evaluation is suitable for students and researchers in medical statistics, statisticians in the pharmaceutical industry, and anyone involved in conducting clinical trials and assessment of health-care technology. |
| adjuvant therapy for her2 positive breast cancer: AJCC Cancer Staging Manual Frederick L, Greene, David L. Page, Irvin D. Fleming, April G. Fritz, Charles M. Balch, Daniel G. Haller, Monica Morrow, 2013-11-21 The American Joint Committee on Cancer's Cancer Staging Manual is used by physicians throughout the world to diagnose cancer and determine the extent to which cancer has progressed. All of the TNM staging information included in this Sixth Edition is uniform between the AJCC (American Joint Committee on Cancer) and the UICC (International Union Against Cancer). In addition to the information found in the Handbook, the Manual provides standardized data forms for each anatomic site, which can be utilized as permanent patient records, enabling clinicians and cancer research scientists to maintain consistency in evaluating the efficacy of diagnosis and treatment. The CD-ROM packaged with each Manual contains printable copies of each of the book’s 45 Staging Forms. |
| adjuvant therapy for her2 positive breast cancer: Advancing the Science of Cancer in Latinos Amelie G. Ramirez, Edward J. Trapido, 2019-11-21 This open access book gives an overview of the sessions, panel discussions, and outcomes of the Advancing the Science of Cancer in Latinos conference, held in February 2018 in San Antonio, Texas, USA, and hosted by the Mays Cancer Center and the Institute for Health Promotion Research at UT Health San Antonio. Latinos – the largest, youngest, and fastest-growing minority group in the United States – are expected to face a 142% rise in cancer cases in coming years. Although there has been substantial advancement in cancer prevention, screening, diagnosis, and treatment over the past few decades, addressing Latino cancer health disparities has not nearly kept pace with progress. The diverse and dynamic group of speakers and panelists brought together at the Advancing the Science of Cancer in Latinos conference provided in-depth insights as well as progress and actionable goals for Latino-focused basic science research, clinical best practices, community interventions, and what can be done by way of prevention, screening, diagnosis, and treatment of cancer in Latinos. These insights have been translated into the chapters included in this compendium; the chapters summarize the presentations and include current knowledge in the specific topic areas, identified gaps, and top priority areas for future cancer research in Latinos. Topics included among the chapters: Colorectal cancer disparities in Latinos: Genes vs. Environment Breast cancer risk and mortality in women of Latin American origin Differential cancer risk in Latinos: The role of diet Overcoming barriers for Latinos on cancer clinical trials Es tiempo: Engaging Latinas in cervical cancer research Emerging policies in U.S. health care Advancing the Science of Cancer in Latinos proves to be an indispensable resource offering key insights into actionable targets for basic science research, suggestions for clinical best practices and community interventions, and novel strategies and advocacy opportunities to reduce health disparities in Latino communities. It will find an engaged audience among researchers, academics, physicians and other healthcare professionals, patient advocates, students, and others with an interest in the broad field of Latino cancer. |
| adjuvant therapy for her2 positive breast cancer: Contrast-Enhanced Mammography Marc Lobbes, Maxine S. Jochelson, 2019-04-29 This book is a comprehensive guide to contrast-enhanced mammography (CEM), a novel advanced mammography technique using dual-energy mammography in combination with intravenous contrast administration in order to increase the diagnostic performance of digital mammography. Readers will find helpful information on the principles of CEM and indications for the technique. Detailed attention is devoted to image interpretation, with presentation of case examples and highlighting of pitfalls and artifacts. Other topics to be addressed include the establishment of a CEM program, the comparative merits of CEM and MRI, and the roles of CEM in screening populations and monitoring of response to neoadjuvant chemotherapy. CEM became commercially available in 2011 and is increasingly being used in clinical practice owing to its superiority over full-field digital mammography. This book will be an ideal source of knowledge and guidance for all who wish to start using the technique or to learn more about it. |
| adjuvant therapy for her2 positive breast cancer: Natural Products in Clinical Trials Atta-ur- Rahman, Shazia Anjum, Hesham El-Seedi, 2018-03-03 Natural products continue to play a key role in drug development. A recent analysis of the drug market in the developed world revealed that 40% of total clinically approved drugs were either unmodified natural products or their semi-synthetic derivatives. This book series focuses on reviews of exciting new bioactive natural products that have huge potential as drugs. It highlights the everlasting importance of natural products in our lives. Each volume brings reviews contributed by eminent scientists in the field. The first volume covers the following topics: - bioactive compounds from marine invertebrates - natural product derived drugs for immunological and inflammatory diseases - clinical trials of curcumin, camptothecin, astaxanthin, and biochanin - antibacterial and antifungal drugs from natural sources - natural products as anti-HIV medicines. |
| adjuvant therapy for her2 positive breast cancer: Hepatotoxicity Hyman J. Zimmerman, 1999 Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury. |
| adjuvant therapy for her2 positive breast cancer: Probably Someday Cancer Kim Horner, 2019-02-15 After learning that she inherited a BRCA2 genetic mutation that put her at high risk for breast and ovarian cancer, Kim Horner’s doctors urged her to consider having a double mastectomy. But how do you decide whether to have a surgery to remove your breasts to reduce your risk for a disease you don’t have and may never get? Horner shares her struggle to answer that question in Probably Someday Cancer. The mother of a one-year-old boy, she wanted to do whatever would give her the best odds of being around for her son and protect her from breast cancer, which killed her grandmother and great-grandmother in their 40s. Which would give her the best chance at a long healthy life: a double mastectomy or frequent screenings to try to catch any cancer early? The answers weren’t that simple. Based on extensive research, interviews, and personal experience, Horner writes about how and why she ultimately opted for a double mastectomy—the same decision actress Angelina Jolie made for a similar genetic mutation—and the surprising diagnosis that followed. The book explores difficult truths that get overshadowed by upbeat messages about early detection and survivorship—the fact that screenings can miss cancers and that even early-stage breast cancers can spread and become fatal. Probably Someday Cancer is about the author’s efforts to push past her fear and anxiety. This book can help anyone facing hereditary risk of breast and ovarian cancer feel less alone and make informed decisions to protect their health and end the devastation that hereditary cancer has caused for generations in so many families. |
| adjuvant therapy for her2 positive breast cancer: Textbook of Breast Cancer Gianni Bonadonna, Gabriel N. Hortobagyi, Pinuccia Valagussa, 2006-01-17 With the current advances in chemotherapy and hormonal drugs for breast cancer, as well as in surgical techniques and procedures, a revised edition of this popular textbook has become increasingly necessary. Completely overhauling the existing material, the editors of this important work have provided a full update of the area, focusing in particular upon the topics where there has been most progress and controversy. |
| adjuvant therapy for her2 positive breast cancer: Modern European and Chinese Contract Law Junwei Fu, 2011-01-01 This comparative study of European and Chinese contract law opens a clear and practical way to identify and understand the differences between the two legal regimes. The author offers a detailed doctrinal comparison of the two systems of contract, focusing on the following fundamental elements: * the importance of socio-economic valuation in Chinese contract law; * the role of judicial interpretation; * pre-contractual liability - penalties for bad faith, disclosure versus concealment; * validity - mistake, fraud, threats, unfair bargaining power; * adaptation and termination - effect of registration and approval rules; * mandatory rules - good faith and fair dealing, the public interest; and * direct application of constitutional law to contracts. The book's special power lies in its extraordinarily thorough comparison of doctrines underlying specific provisions of such instruments as the Contract Law of the People's Republic of China (CLC), the General Principles of the Civil Law of the People's Republic of China (GPCL), the Principles of European Contract Law (PECL), and the Draft Common Frame of Reference (DCFR), as well as analysis of judicial cases. |
| adjuvant therapy for her2 positive breast cancer: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| adjuvant therapy for her2 positive breast cancer: מסגור תקשורתי , 2006 |
| adjuvant therapy for her2 positive breast cancer: The Breast K. I. Bland, Edward M. Copeland, 2009 Offering the most comprehensive, up-to-date information on the diagnosis and management of, and rehabilitation following, surgery for benign and malignant diseases of the breast, this surgical reference is now in a new edition available in both print and online for easy, convenient access to the absolute latest advances. |
| adjuvant therapy for her2 positive breast cancer: Contrast-Enhanced Digital Mammography (CEDM) Jacopo Nori, Maninderpal Kaur, 2018-10-09 This book offers a comprehensive, practical resource entirely devoted to Contrast-Enhanced Digital Mammography (CEDM), a state-of-the-art technique that has emerged as a valuable addition to conventional imaging modalities in the detection of primary and recurrent breast cancer, and as an important preoperative staging tool for women with breast cancer. CEDM is a relatively new breast imaging technique based on dual energy acquisition, combining mammography with iodine-based contrast agents to display contrast uptake in breast lesions. It improves the sensitivity and specificity of breast cancer detection by providing higher foci to breast-gland contrast and better lesion delineation than digital mammography. Preliminary results suggest that CEDM is comparable to breast MRI for evaluating the extent and size of lesions and detecting multifocal lesions, and thus has the potential to become a readily available, fast and cost-effective examination. With a focus on the basic imaging principles of CEDM, this book takes a practical approach to breast imaging. Drawing on the editors’ and authors’ practical experience, it guides the reader through the basics of CEDM, making it especially accessible for beginners. By presenting the key aspects of CEDM in a straightforward manner and supported by clear images, the book represents a valuable guide for all practicing radiologists, in particular those who perform breast imaging and have recently incorporated or plan to incorporate CEDM into their diagnostic arsenal. |
| adjuvant therapy for her2 positive breast cancer: Breast Cancer , 2003 |
| adjuvant therapy for her2 positive breast cancer: NCCN Guidelines for Patients® Invasive Breast Cancer National Comprehensive Cancer Network® (NCCN®), 2023-04-18 [OFFICIAL CURRENT VERSION] From the National Comprehensive Cancer Network (NCCN) comes this essential guide to Invasive Breast Cancer. Based on clinical treatment guidelines used by doctors and oncology professionals around the world, these NCCN Guidelines for Patients help patients and caregivers talk with their doctors and make treatment decisions. Topics include: Breast cancer basics, Testing for breast cancer, Breast cancer staging, Treating breast cancer, Surgery first, Preop treatment first, The breast after surgery, Recurrence, Making treatment decisions, Words to know, NCCN Contributors, NCCN Cancer Centers, Index |
| adjuvant therapy for her2 positive breast cancer: A Theranostic and Precision Medicine Approach for Female-Specific Cancers Rama Rao Malla, Ganji Purnachandra Nagaraju, 2020-11-25 A Theranostic and Precision Medicine Approach for Female-Specific Cancers provides information regarding ongoing research and clinical data surrounding female specific cancers (breast, cervical, ovarian and endometrial cancers). The book encompasses detailed descriptions about diagnostics and therapeutic options for easy understanding, focusing on the subject matter with a broader range of treatment options. In addition, it explores new theranostics, i.e., diagnostic, therapeutic and precision medicine strategies currently being developed for FSCs. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of biomedical field who need to understand the most recent and promising approaches to manage FSCs. Explores new diagnostic biomarkers surrounding the early detection and prognosis of FSCs Examines new genetic and molecularly targeted approaches for the treatment of these aggressive diseases Discusses new theranostic approaches that combine diagnosis and treatment through the use of nanotechnology in FSCs Addresses how these various advances can be integrated into a precision and personalized medicine approach that can eventually enhance patient care |
| adjuvant therapy for her2 positive breast cancer: DeVita, Hellman, and Rosenberg's Cancer Vincent T. DeVita, Steven A. Rosenberg, Theodore S. Lawrence, 2018-11-16 Publisher's Note: Products purchased from 3rd Party sellers are not guaranteed by the Publisher for quality, authenticity, or access to any online entitlements included with the product. Now updated online for the life of the edition, DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition keeps you up to date in this fast-changing field. Every quarter, your eBook will be updated with late-breaking developments in oncology, including new drugs, clinical trials, and more. |
| adjuvant therapy for her2 positive breast cancer: DeVita, Hellman, and Rosenberg's Cancer Vincent T DeVita Jr, Steven A Rosenberg, Theodore S Lawrence, 2022-09-21 The standard-setting text in oncology for 40 years, DeVita, Hellman and Rosenberg’s Cancer: Principles and Practice of Oncology, 12th Edition, provides authoritative guidance and strategies for managing every type of cancer by stage and presentation. Drs. Vincent T. DeVita, Jr., Theodore S. Lawrence, and Steven A. Rosenberg oversee an outstanding team of expert contributing authors who keep you up to date and fully informed in this fast-changing field. This award-winning reference is also continually updated on Health Library and VitalSource platforms for the life of the edition. |
| adjuvant therapy for her2 positive breast cancer: The American Cancer Society's Oncology in Practice The American Cancer Society, 2018-05-01 Developed by the American Cancer Society this new textbook designed for a wide range of learners and practitioners comprehensively addresses all aspects of clinical management for cancer taking a balanced, authoritative and, -where possible- evidence-based stance and may be used in conjunction with the book, The American Cancer Society's Principles of Oncology: Prevention to Survivorship. Edited by leading clinicians in the field and a stellar contributor list from the US and Europe, this book is written in an easy to understand style by multidisciplinary teams of medical oncologists, radiation oncologists and other specialists, reflecting day-to-day decision-making and clinical practice. Input from pathologists, surgeons, radiologists, and other specialists is included wherever relevant and comprehensive treatment guidelines are provided by expert contributors where there is no standard recognized treatment. This book is an ideal resource for anyone seeking a practical understanding of the field of oncology. |
Adjuvants and Vaccines | Vaccine Safety | CDC
Dec 20, 2024 · An adjuvant is an ingredient used in some vaccines that helps create a stronger immune response in people receiving the vaccine. In other words, adjuvants help vaccines work better. Adjuvants help the body to produce an immune response strong enough to protect the person from the disease he or she is being vaccinated against.
ADJUVANT Definition & Meaning - Merriam-Webster
The meaning of ADJUVANT is serving to aid or contribute : auxiliary. How to use adjuvant in a sentence. Did you know?
Adjuvant - Wikipedia
In pharmacology, an adjuvant is a drug or other substance, or a combination of substances, that is used to increase the efficacy or potency of certain drugs. Specifically, the term can refer to: Adjuvant therapy in cancer management; Analgesic adjuvant in pain management; Immunologic adjuvant in vaccines
Adjuvant therapy: Treatment to keep cancer from returning
May 2, 2024 · Adjuvant treatments may last from just a few weeks to as long as 10 years. Understand what the recommendations are and why your healthcare professional is making them. Chances of staying cancer-free.
Immunologic adjuvant - Wikipedia
In immunology, an adjuvant is a substance that increases or modulates the immune response to a vaccine. [1] The word "adjuvant" comes from the Latin word adiuvare, meaning to help or aid.
Real- world treatment patterns of adjuvant endocrine …
factor receptor 2 positive (HER2) and one third to one + half of HER2 breast cancers are also HR+ .1,2 The con+ - current expression with resulting cross-talk of hormones (estrogen and/or …
BC Cancer Protocol Summary for Adjuvant Therapy for …
Adjuvant Therapy for Breast Cancer using Trastuzumab Emtansine (KADCYLA) Protocol Code UBRAJKAD . Tumour Group . Breast : Contact Physician . Dr Stephen Chia : ... Von Minckwitz …
Economic evaluation of trastuzumab in HER2-positive early …
3. Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast …
ASCO Biomarkers for Adjuvant Endocrine and ... - ASCO …
Apr 19, 2022 · For patients with early-stage ER-positive, HER2-negative breast cancer, which biomarkers should be used to guide ... Biomarkers in Adjuvant Therapy in Early-Stage Breast …
Ribociclib plus Endocrine Therapy in Early Breast Cancer
Months Percentage of Patients 100 80 90 70 60 50 40 30 20 10 0 0 6 12 18 24 30 36 42 48 Ribociclib + NSAI 90.4 HR for invasive disease, recurrence, or death, 0.75
How We Treat Locally Advanced HER2-Positive Breast Cancer
Expert Consensus support neoadjuvant systemic therapy for locally advanced HER2-positive breast cancer, along with surgery, radiation therapy, and (when appropriate) ... the treatment of …
Official Title: A RANDOMIZED, MULTICENTER, DOUBLE …
COMBINATION WITH TRASTUZUMAB AS ADJUVANT THERAPY AFTER SURGERY AND CHEMOTHERAPY IN PATIENTS WITH EARLY-STAGE OR LOCALLY ADVANCED HER2 …
Recent Developments in HER2-Directed Therapy in Breast …
tor, was approvedfor extended adjuvant therapy based on the pivotal phase III trial ExteNET. The primary endpoint of 2-year invasive disease-free survival (iDFS) was reported in 2016 followed …
Prognostic impact of HER2-low positivity in patients with HR …
Adjuvant therapy for patients with hormone receptor (HR)‑positive, human epidermal growth ... in HER2-positive but also in HER2-low breast cancer4, 5. HER2 is an important indicator of …
Dana-Farber Breast Oncology Center - Amazon Web Services
use of abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of high-risk, node-positive, early-stage, hormone receptor-positive (HR+), HER2-negative breast …
Targeted therapeutic options and future perspectives for …
HER2-positive breast cancer may result in resistance to non- ... determining whether the patients should undertake anti-HER2 therapy.37 IHC assays have been ... 37,45 National Surgical …
Adjuvant T-DM1 versus trastuzumab in patients with residual …
Apr 28, 2021 · (HER2)-targeted therapy to standard treatment regimens for HER2-positive early breast cancer (EBC) has dramatically improved survival in this patient population.1-3 Nonethe …
How We Treat HER2-Positive Metastatic Breast Cancer
Nov 26, 2021 · HER2-positive breast cancer who had progressed follow-ing treatment that included an anthracycline, a taxane, and trastuzumab to either capecitabine alone (2,500 …
HER2-targeted therapies for HER2-positive early-stage …
clinical practice for patients with HER2+ EBC. KEYWORDS HER2-positive breast cancer, early-stage breast cancer, targeted therapy, neoadjuvant therapy, adjuvant therapy 1 Introduction …
Adjuvant and neoadjuvant therapy with or without CDK4/
Sep 12, 2024 · Adjuvant and neoadjuvant therapy with or without CDK4/ 6 inhibitors in HR+/HER2- early breastcancer:asystematicreview and meta-analysis Zhihao Zhang†, Xin …
Novartis ribociclib (Kisqali®) recognized as Category 1 …
Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Oct 24, 2024 …
Poster Session 3 12:30 – 2:00 p.m. Thursday, December 12
Improve Breast Cancer Risk Prediction in Minority Women Sara Wallam P3-02-09: Correlation between risk groups and molecular subtype of breast cancer with metabolic syndrome and …
Final Efficacy Results of Neratinib in HER2-positive Hormone …
of disease recurrences and death among patients with HER2-positive (HER2þ) early breast cancer (eBC) when added to adjuvant chemotherapy.1-3 After the initial trials of trastuzumab, …
GS3-03: Impact of Anthracyclines in High Genomic Risk Node …
HR+/HER2- Breast Cancer Presenting Author(s): Nan Chen ... containing chemotherapy for patients with hormone receptor-positive (HR+) breast cancer. Thus, ... score (RS) has not been …
Axillary Management for Patients With In-Situ and Invasive …
systemic therapy, adjuvant vs neoadjuvant. The radiation oncologist can offer no ... 3. ≥70 years of age with cT1-2N0 hormone receptor positive breast cancer • 62% of patients in the CALGB …
Position Paper on the Value of Extended Adjuvant Therapy …
HER2-positive breast cancert · Co-positive breast cancer · Early breast cancer · Extended adjuvant therapy · Neratinib Abstract Background: In August 2018, neratinib – an oral, ...
Adjuvant trastuzumab cardiotoxicity in patients over 60 years …
Background: Adjuvant Trastuzumab with chemotherapy is the gold standard for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (HER2+ EBC). Older patients …
Recurrence risk prediction model in HER2-positive early …
Recurrence risk prediction model in HER2-positive early breast cancer after HER2-targeted therapy. Qingyao Shang, Alison M. Yu, Haotian Zou, Youwen He, Xin Wang, Sheng Luo; …
Trastuzumab Emtansine for Residual Invasive HER2 …
patients with HER2-positive early breast cancer.15 Here, we report the primary results of the KATHERINE trial, which compared adjuvant T-DM1 with trastuzumab in patients who had …
Optimal Adjuvant Chemotherapy and Targeted Therapy for …
May 20, 2024 · Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—Cyclin-Dependent Kinase 4 and 6 ... HER2-negative, node-positive, early breast …
Biomarker Data From the Phase III KATHERINE Study of …
Residual Invasive Disease After Neoadjuvant Therapy for HER2-Positive Breast Cancer Carsten Denkert 1 , Chiara Lambertini 2 , Peter A. Fasching 3 , Katherine L. Pogue-Geile 4 , Max S. …
Kadcyla®- Trastuzumab Emtansine (Breast) - SWAG Cancer …
months of completing adjuvant therapy. (NICE TA458) Adjuvant treatment of HER2-positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after …
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, …
Adjuvant Therapy for HER2-Positive Breast Cancer O verexpression of the human epi-dermal growth factor receptor type 2 (HER2) occurs in approximately 15 to ... Adjuvant Therapy for …
A Retrospective Analysis of Metronomic Cyclophosphamide, …
Positive, HER2 Negative Breast Cancer Lindsey Jung, 1 Abby Miske, 1 Amy Indorf, 1 Kate Nelson, 2 Vijayakrishna K Gadi, 3 Kalyan Banda 4 Abstract We evaluated the efficacy and …
Adjuvant S-1 plus endocrine therapy for oestrogen receptor …
metastatic breast cancer. We examined adjuvant treatment with S-1 in patients with oestrogen receptor (ER)-positive and HER2-negative primary breast cancer. Methods We did a …
How we Treat HR-Positive, HER2-Negative Early Breast Cancer
Keywords: adjuvant •breast cancer chemotherapy early stage endocrine therapy genomic platforms • HER2-negative• high-risk• HR-positive• neoadjuvant Breast cancer (BC) is the most …
How we treat patients with metastatic HER2-positive breast …
HER2-positive breast cancer represents 15%-20% of breast malignancies and is characterized by an aggressive behavior and high recurrence rates. Anti-HER2-directed agents represent the …
T-DM1 for residual, invasive, HER2-positive breast cancer
therapy for them”, said Geyer. He added that the effectiveness of T-DM1 in patients with residual invasive cancer after neoadjuvant therapy could make it easier for researchers to investigate …
Ribociclib with an aromatase inhibitor for adjuvant treatment …
3.1 Breast cancer is the most common cancer in the UK. Hormone receptor-positive HER2-negative breast cancer is the most common subtype, accounting for about 68% of all breast …
Duration of extended adjuvant therapy with neratinib in …
tyrosine kinase inhibitor of HER1, HER2 and HER4.1 – ExteNET, an international, randomized, placebo‑controlled phase III trial (N=2840), showed that a 1‑year course of neratinib 240 …
Adjuvant trastuzumab emtansine in HER2-positive breast …
Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may …
Cost-utility analysis of adjuvant trastuzumab therapy for …
Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines Anne Julienne Genuino1,2, Usa Chaikledkaew1,3*, Anna Melissa Guerrero2, …
Dana-Farber Breast Oncology Center
In patients with early stage HR+/HER2- breast cancer who would have met eligibility criteria for BOTH the monarchE and NATALEE trials, the currently preferred CDK4/6 inhibitor is …
Trastuzumab plus Adjuvant Chemotherapy for Operable …
taxel for HER2-positive metastatic breast cancer. 1 The benefit of this approach in patients with meta-static disease and the poor prognosis of HER2-pos-itive breast cancer 2,3 motivated the ...
Neoadjuvant Chemotherapy, Endocrine Therapy, and …
without surgical information. Among postmenopausal patients with HR-positive, HER2-negative disease, hormone therapy can be used to downstage disease. Patients with node-positive or …
Neoadjuvant Systemic Therapy in the Management of Breast …
appropriate adjuvant endocrine therapy, anti-HER2/neu targeted therapy, and in some cases additional chemotherapy. 11. Clinical trial participation should be considered. b. Neoadjuvant …
HER2-positive breast cancer - The Lancet
The success of neoadjuvant therapy in HER2-positive early breast cancer is especially acknowledged, as pertuzumab ... Event-free survival after the confirmatory adjuvant trial …
Evolution of Adjuvant Chemotherapy for Breast Cancer: …
In a separate analysis for HER2-positive tumours, 90% of the patients treated with trastuzumab were disease-free at 100 months follow up, ... Chemotherapy has represented the first …
Poster Session 4 5:30 – 7:00 p.m. Thursday, December 12
complete response (pCR) in early-stage HER2-positive breast cancer patients undergoing neoadjuvant therapy Bei Jiang P4-01-19: Clinical impact of MRD detection via ctDNA tumor- ...
Adjuvant Pertuzumab and Trastuzumab in Early HER2 …
Jun 5, 2017 · Pertuzumab and Trastuzumab in HER2-Positive Breast Cancer C ... py plus trastuzumab as adjuvant treatment for patients with HER2-positive early breast cancer. ... or …
Official Title: A RANDOMIZED, MULTICENTER, DOUBLE …
early-stage or locally advanced her2-positive breast cancer nct number: nct02586025 : document date: protocol ; version 4: 06 december 2016 . title 06-dec-2016 18:25:11 date and time (utc) ...
National Comprehensive Cancer Network (NCCN) Clinical …
concurrently with endocrine therapy. o Adjuvant HER2-targeted therapy with or without endocrine therapy may be delivered concurrently with RT. • Accelerated Partial Breast Irradiation …
NCCN Clinical Practice Guidelines in Oncology (NCCN …
Preoperative/Adjuvant Therapy Regimens (BINV-L) Principles of Preoperative Systemic Therapy (BINV-M) ... For adult patients with advanced unresectable or metastatic HER2-positive breast …
Abemaciclib plus endocrine therapy for hormone receptor …
current standard-of-care adjuvant endocrine therapy for patients with hormone receptor-positive, HER2-negative, node-positive early breast cancer at a high risk of recurrence on the basis of …
Biomarker Data from KATHERINE: A Phase 3 Study of …
HER2 expression. is generally associated with better outcomes in response to HER2-targeted therapy. 1,2 • PIK3CA mutation . is a knownmarker of poor prognosis in MBC, 2,3. but data are …
